drugset
drugset / Trial / NCT03657355

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

NCT03657355 ↗

Phase 1 Completed 63 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

Timeline

Start
2018-09-07
Primary completion
2019-08-08
Completion
2019-08-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral
Subject Daridorexant Small molecule 100 mg Oral
Subject Daridorexant Small molecule 150 mg Oral
Comparator Suvorexant Small molecule 150 mg Oral
Comparator Zolpidem Small molecule 30 mg Oral

Indications

No indication recorded.